AI drug discovery
The multiyear agreement will focus on speeding clinical trials and drug development in oncology and nonalcoholic steatohepatitis.
Also, Genesis MedTech has acquired Chinese valve replacement device maker JC Medical.
This news comes just months after Exscientia went public.
The partners aim to accelerate the discovery of novel anti-tubercular drug candidates.
The company said the latest round brings its total raise to $47 million.
This collaboration will work with an unnamed pharma company in Japan to know how its drugs behave compared to rival products.
From drug discovery to forecasting kidney disease AI could be the next game-changer in healthcare.
The company plans to use this money to use its therapeutics program in human clinical trials.
The deep learning framework proposed by Ping An learns molecular representations from large volumes of unlabelled molecules.
The partners will use a new method of training AI known as transformer neural networks.